Welcome to our dedicated page for Barnes Group news (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barnes Group stock.
Barnes Group Inc. (NYSE: B) is a leading international industrial and aerospace manufacturer and service provider, serving a wide array of markets and customers. The company’s highly engineered products, industrial technologies, and innovative solutions are essential in transportation, manufacturing, healthcare, and technology sectors worldwide.
With approximately 4,700 employees across more than 60 locations on four continents, Barnes Group upholds its long tradition of excellence in precision manufacturing and logistics solutions. The company operates under two main segments: Industrial and Aerospace.
The Industrial segment focuses on manufacturing precision parts and systems for critical applications in transportation, industrial equipment, and consumer products. The Aerospace segment provides machined components and assemblies for OEM turbine engines, airframes, industrial gas turbines, and military applications. Barnes Group’s products are integral to the performance and reliability of these critical systems.
In recent years, Barnes Group has invested significantly in leading-edge technologies to enhance its capabilities and explore breakthrough markets. This forward-thinking approach ensures the company remains at the forefront of innovation, meeting the evolving needs of its diverse customer base.
Barnes Group’s financial health is robust, underscored by strategic partnerships and consistent performance. The company's commitment to sustainable growth and operational excellence is evident in its dedication to quality and customer satisfaction.
For the latest updates and news, stay tuned to Barnes Group Inc.’s announcements and developments, which reflect its dynamic presence in the global market.
Rhea-AI Summary
BioArctic AB's (Nasdaq Stockholm: BIOA B) partner Eisai announced that Leqembi has been approved in China as a treatment for mild cognitive impairment and mild AD dementia due to Alzheimer's disease. Leqembi is the first approved treatment shown to reduce the rate of disease progression and slow cognitive and functional decline. The drug is based on the large global Phase 3 Clarity AD study, where it met its primary endpoint and all key secondary endpoints with statistically significant results. Eisai estimates that there are 17 million patients with MCI or mild dementia due to AD in China today, which is expected to increase with the aging of the population. BioArctic has a long-term collaboration with Eisai regarding the development and commercialization for Leqembi. Eisai is responsible for the clinical development, applications for market approval, and commercialization of the drug. BioArctic has no development costs for Leqembi in Alzheimer's disease and is entitled to payments in connection with certain regulatory approvals, and sales milestones as well as royalties on global sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
-
News
Rhea-AI Summary
ARound (NASDAQ: STGW) collaborates with Immersal to develop a turn-key WebAR solution for stadium AR, aiming to enhance fan engagement and create new avenues for brands to connect with audiences. The partnership marks a significant milestone in bringing innovative AR experiences to live sports and entertainment, with plans to announce their inaugural collaboration with a major sports league next month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
-
Rhea-AI Summary
Integrum (Nasdaq First North Growth Market: INTEG B) establishes a Center of Excellence in Kyiv to spearhead orthopedic treatment using OPRA™ Implant System for individuals who have suffered limb loss, addressing the increased need for amputee care in Ukraine following the Russian invasion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
Rhea-AI Summary
Barnes Group Inc. (NYSE: B) will release its Q4 and full year 2023 financial results on February 16, 2024, before the market opens. A conference call to discuss the results and the Company’s outlook will also be hosted at 8:30 a.m. (ET) on that day. The public can access the conference through a live audio webcast on the Investor Relations section of the Barnes website. Supplemental materials will be posted prior to the call, and a recorded playback will be available until February 23, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
-
Rhea-AI Summary
BioArctic AB's (Nasdaq Stockholm: BIOA B) partner Eisai announced the launch of LEQEMBI in Japan on December 20, following its inclusion in the price listing on the Japan National Health Insurance drug price list. The product obtained approval for the indication of slowing progression of mild cognitive impairment and mild dementia due to Alzheimer's disease in Japan on September 25, 2023. LEQEMBI selectively binds to soluble and insoluble amyloid-beta aggregates, reducing Aβ protofibrils and plaques in the brain. The launch in Japan makes it the second country to have the product on the market, following the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
-
Rhea-AI Summary
Hexagon's Manufacturing Intelligence division (HEX) has partnered with JSOL Corporation to accelerate virtual prototyping of electrified powertrains through multi-physics simulation. This strategic collaboration aims to address the rapid electrification of industries like automotive and aerospace transport, offering comprehensive simulation solutions for system design problems in the virtual world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
Rhea-AI Summary
Infor® (INF) partners with ETQ to enhance quality management and environmental, health, and safety solutions for various industries. ETQ Reliance offers QMS and EHS applications, while Infor CloudSuite manages product and quality specifications, inspections, and track & trace capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
-
Rhea-AI Summary
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023. The awards celebrate the best innovations and achievements of the international biopharma industry. Lecanemab is recognized for its excellence in pharmaceutical development, being the first and only treatment approved in Japan and the United States shown to reduce the rate of disease progression and to slow cognitive and functional decline in Alzheimer's disease patients. The success of the Phase 3 Clarity AD study of lecanemab led to the award for Clinical Advance of the Year. BioArctic and Eisai are preparing for a joint commercialization of lecanemab in the Nordic region.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
-
Rhea-AI Summary
Integrum (Nasdaq First North Growth Market: INTEG B) plans to submit a PMA application to the FDA for the use of OPRA in transhumeral amputations based on existing clinical data. The company aims to broaden the regulatory approval in the US for the OPRA Implant System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
Rhea-AI Summary
INTEG B - Integrum (publ) Expects Higher Q2 Revenue, Operating Profit, and Cash Flow, Preliminary Figures Show 36.2% Revenue Increase and 611.1% Operating Profit Surge
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
FAQ
What is the current stock price of Barnes Group (B)?
The current stock price of Barnes Group (B) is $46.82 as of November 22, 2024.
What is the market cap of Barnes Group (B)?
The market cap of Barnes Group (B) is approximately 2.4B.
What does Barnes Group Inc. specialize in?
Barnes Group Inc. specializes in manufacturing highly engineered products and providing industrial technologies and innovative solutions across transportation, manufacturing, healthcare, and technology sectors.
How is Barnes Group Inc. structured?
Barnes Group Inc. operates under two main segments: Industrial, which focuses on precision parts for transportation and industrial applications, and Aerospace, which provides components and assemblies for turbine engines and airframes.
Where are Barnes Group Inc.'s operations located?
Barnes Group Inc. operates in more than 60 locations worldwide, spanning four continents.
How many employees does Barnes Group Inc. have?
Barnes Group Inc. employs approximately 4,700 dedicated professionals.
What are the key markets served by Barnes Group Inc.?
Barnes Group Inc. serves key markets including transportation, industrial equipment, consumer products, and aerospace.
What are some recent achievements of Barnes Group Inc.?
Barnes Group Inc. has made significant investments in leading-edge technologies and breakthrough markets, enhancing its capabilities and maintaining its leadership in precision manufacturing and logistics solutions.
What makes Barnes Group Inc. products unique?
Barnes Group Inc.'s products are highly engineered and critical to the performance and reliability of systems in transportation, industrial equipment, and aerospace applications.
How does Barnes Group Inc. ensure quality and customer satisfaction?
Barnes Group Inc. is committed to sustainable growth, operational excellence, and continuous investment in technology to meet and exceed customer expectations.
Who are the typical customers of Barnes Group Inc.?
Barnes Group Inc. serves a wide range of customers in sectors such as transportation, industrial equipment, medical and personal care, mobility, and packaging.
What are the future plans of Barnes Group Inc.?
Barnes Group Inc. aims to continue building on its tradition of excellence in precision manufacturing and expand into new markets through continuous innovation and strategic investments.
Barnes Group Inc.
Nasdaq:B
B Stock Data
2.38B
46.22M
9.17%
93.7%
1.44%
Specialty Industrial Machinery
Miscellaneous Fabricated Metal Products
United States of America
BRISTOL